If you’ve heard of hepatitis, you probably know it has something to do with the liver. But there’s a whole family of hepatitis viruses, each with its own personality when it comes to how it spreads, what it does to your body, and how we can prevent or treat it. Let’s walk through the three most common types—hepatitis A, B, and C—and then dive into a controversy that’s making headlines right now: the hepatitis B vaccine.
What Is Hepatitis, Anyway?
At its core, hepatitis just means inflammation of the liver. Your liver is a workhorse organ that filters toxins, produces essential proteins like albumin, processes amino acids, and stores energy. When a hepatitis virus attacks it, the inflammation can range from a minor inconvenience to a life-threatening condition. The three main culprits—hepatitis A, B, and C viruses—are completely different organisms that just happen to target the same organ.
Hepatitis A: The Food and Water Troublemaker
Hepatitis A is often called “traveler’s hepatitis” because it spreads through food and water that are contaminated with fecal matter. Think of it as the virus you might pick up from eating unwashed produce, drinking contaminated water, or consuming raw shellfish from polluted waters. Other risk factors include unprotected sex and IV drug use. According to the CDC, there were an estimated 3,300 acute infections in 2023 in the United States.
The good news about hepatitis A is that it typically heals itself within 2 months. When symptoms appear—which take about 15 to 50 days after infection—they can include jaundice (that yellowing of the skin and eyes), fever, fatigue, nausea, and dark urine. Many young children don’t show any symptoms at all. The virus doesn’t become chronic, and once you’ve had it, your body produces antibodies that protect you for life.
Prevention is straightforward: there’s a safe and effective vaccine, and basic hygiene goes a long way. Wash your hands thoroughly, especially after using the bathroom and before preparing food. When traveling to areas with questionable water quality, stick to bottled or boiled water and avoid washing raw food in local water.
Treatment is mostly supportive—rest, fluids, and time. Your liver does the healing work itself.
Hepatitis B: The Blood and Body Fluid Virus
Hepatitis B is where things get more serious. This virus spreads through blood and other body fluids, which means it can be transmitted through sexual contact, sharing needles, or from mother to baby during childbirth. Healthcare workers are especially at risk from needle sticks and sharps injuries. It’s a highly infectious and tough virus that can live on surfaces for up to a week. Even tiny amounts of dried blood on seemingly innocent things like razors, nail clippers, or toothbrushes can potentially spread the infection.
According to the CDC, there were an estimated 14,400 acute infections in 2023, Approximately 640,000 adults were living with chronic hepatitis B during the 2017-2020 period and that’s what makes it particularly concerning: while the hepatitis B virus often causes short-term illness, it can become chronic.
The incubation period is long—typically 90 days with a range of 60 to 150 days. When symptoms do appear, they mirror hepatitis A: jaundice, fatigue, abdominal pain, nausea, and dark urine. But here’s the frightening part: most young children and many adults show no symptoms at all, meaning they can spread the virus without knowing they’re infected.
The chronic infection risk varies dramatically by age. If you’re infected as a newborn, you have a 90% chance of developing chronic hepatitis B. For adults, the risk drops to under 5%. Those with chronic infection face serious long-term consequences—15% to 25% of people with chronic infection develop serious liver disease, including cirrhosis, liver failure, or liver cancer.
Treatment for acute hepatitis B is supportive, but several antiviral medications are available for people with chronic infection. These don’t completely eradicate the disease but produce a “functional cure” that significantly slows liver damage and reduces complications.
Prevention is critical. There’s a highly effective vaccine—we’ll talk more about the controversy surrounding it in a moment. Avoiding exposure to infected blood and body fluids is essential. This means safe sex practices, never sharing needles or personal care items that might have blood on them, and ensuring proper sterilization of medical and tattooing equipment.
Hepatitis C: The Silent Epidemic
Hepatitis C is transmitted primarily through blood-to-blood contact. The most common route is sharing needles among people who inject drugs, though it can also spread through contaminated medical equipment, and rarely through sexual contact. Mother-to-child transmission during childbirth is possible but uncommon. Screening of blood products has made transfusion related infections rare. About 10% of cases have no identified source.
What makes hepatitis C insidious is its stealthy nature. Many people with hepatitis C don’t have symptoms, and acute hepatitis with jaundice is rare, occurring in only about 10% of infections. The symptoms that do appear—fatigue, mild flu-like feelings—are easily dismissed. Meanwhile, the majority of people (60-70%) develop chronic infection. I recommend a screening blood test at least once for all adults over age 55, as they are the group most likely to have hepatitis C without an identifiable source.
The incubation period ranges widely, from 2 weeks to 6 months, typically 6 to 9 weeks. Without treatment, chronic hepatitis C can lead to cirrhosis and liver cancer over decades. Before modern treatments, it was a leading cause of liver transplants.
Treatment for hepatitis C has undergone a revolution. The old approach—interferon injections combined with ribavirin—had terrible side effects and worked in only about half of patients. Today, we have direct-acting antivirals (DAAs), which can cure more than 95% of cases with just 8-12 weeks of well-tolerated oral medication. These drugs target specific proteins the virus needs to replicate, essentially starving it out of existence. The treatment is so effective that hepatitis C is now considered a curable disease.
Prevention focuses on avoiding blood-to-blood contact. Never share needles, syringes, or any drug equipment. If you’re getting a tattoo or piercing, ensure the facility follows proper sterilization procedures. Healthcare workers should follow standard precautions with blood and body fluids. Unfortunately, there’s no vaccine for hepatitis C yet, though researchers continue working on one.
The Hepatitis B Vaccine Controversy: What’s Really Happening
Now let’s address the elephant in the room—the recent controversy over the hepatitis B vaccine for newborns. This topic exploded in the news in December 2025, and it’s worth understanding what’s currently going on versus what the science says.
The Recent Development
On December 5, 2025, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted 8-3 to recommend hepatitis B vaccination at birth only for infants born to mothers who test positive for the virus or whose status is unknown. This reverses decades of policy that recommended universal hepatitis B vaccination for all newborns within 24 hours of birth.
The Arguments For Changing the Policy
Some ACIP members raised concerns about vaccine safety and parental hesitancy. Committee member Retsef Levi heralded the move as “a fundamental change in the approach to this vaccine,” which would encourage parents to “carefully think about whether they want to take the risk of giving another vaccine to their child”. The controversy includes historical concerns about possible links between the hepatitis B vaccine and conditions like multiple sclerosis, autism, and other autoimmune disorders.
What Science Actually Shows
The evidence on vaccine safety is quite robust. Concerns about multiple sclerosis emerged in France in the 1990s. Since then, a large body of scientific evidence shows that hepatitis B vaccination does not cause or worsen MS. The World Health Organization’s Global Advisory Committee on Vaccine Safety has concluded there is no association between the hepatitis B vaccine and MS. It is one of the safest vaccines studied.
As for other safety concerns, CDC reviewed VAERS reports from 2005-2015 and found no new or unexpected safety concerns. The most common side effects are minor: soreness at the injection site, headache, and fatigue lasting 1-2 days.
Why the Universal Birth Dose Matters
The scientific and medical communities have strongly opposed this policy change. The American Academy of Pediatrics states that from 2011-2019, rates of reported acute hepatitis B remained low among children and adolescents, likely explained in part by the implementation of childhood hepatitis B vaccine recommendations published in 1991.
Here’s why newborns are so vulnerable: infected infants have a 90% chance of developing chronic hepatitis B, and a quarter of those will die prematurely from liver disease when they become adults.
The “just target high-risk babies” approach has a major flaw: the CDC estimates about 640,000 adults have chronic hepatitis B, but about half don’t know they’re infected. Before universal vaccination, about half of infected children under 10 got it from their mothers—the rest contracted it through other exposures not identified by maternal screening.
The Global Context
Claims that the U.S. is an outlier don’t hold up. As of September 2025, 116 of 194 WHO member states recommend universal hepatitis B birth dose vaccination. European countries that do not recommend a universal birth dose have a much lower hepatitis B incidence rate and more robust antenatal maternal screening. The majority still recommend vaccination at two to three months.
The Bottom Line
All three types of hepatitis pose serious health risks, but we have powerful tools to prevent and treat them. Hepatitis A and B have safe, effective vaccines that have dramatically reduced disease rates. Hepatitis C, while lacking a vaccine, is now curable with modern antiviral medications.
The hepatitis B vaccine controversy highlights a broader tension in public health: balancing individual autonomy with community protection. The scientific evidence strongly supports the vaccine’s safety and the effectiveness of universal newborn vaccination in preventing a disease that can be fatal. Multiple studies, decades of safety data, and recommendations from medical organizations worldwide back this up.
For parents making decisions about their newborns, the facts are these: hepatitis B is a serious disease with a high risk of becoming chronic in infants, the vaccine is highly effective at preventing infection, and extensive safety monitoring has found it to be safe with only minor, temporary side effects. As hepatitis research continues, we’re seeing remarkable progress—from the near-eradication of hepatitis A in vaccinated populations to the transformation of hepatitis C from a chronic, often fatal disease to a curable one. These advances remind us how far we’ve come in understanding and combating these liver viruses.
Sources
- Centers for Disease Control and Prevention (https://www.cdc.gov)
- World Health Organization (https://www.who.int)
- Cleveland Clinic (https://my.clevelandclinic.org)
- National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov)
- American Academy of Pediatrics (https://www.aap.org)
- PBS NewsHour (https://www.pbs.org)
- FactCheck.org (https://www.factcheck.org)
- Government of Quebec (https://www.quebec.ca/en/health/health-issues/stbbis/hepatitis-a-b-and-c)
America’s Healthcare Paradox: Why We Pay Double and Get Less
By John Turley
On January 5, 2026
In Commentary, Medicine
The healthcare debate in America often circles back to a fundamental question: should we move toward a single-payer system, or is our current mixed public-private model the better path forward? It’s a conversation that gets heated quickly, but when you strip away the politics and look at how different systems actually function around the world, some interesting patterns emerge.
What We Mean by Single-Payer
A single-payer healthcare system means that one entity—usually the government or a government-related organization—pays for all covered healthcare services. Doctors and hospitals can still be private (and usually are), but instead of dealing with dozens of different insurance companies, they bill one source. It’s a lot like Medicare, which is why proponents often call it “Medicare-for-all”.
The key thing to understand is that single-payer isn’t necessarily the same as socialized medicine. In Canada’s system, for instance, the government pays the bills, but doctors are largely in the private sector and hospitals are controlled by private boards or regional health authorities rather than being part of the national government. Compare that to the UK’s National Health Service, where many hospitals and clinics are government-owned and many doctors are government employees.
America’s Current Patchwork
The United States operates what might charitably be called a “creative” approach to healthcare—a complex mix of employer-sponsored private insurance, government programs like Medicare, Medicaid and the VA system, individual marketplace plans, and direct out-of-pocket payments. Government already pays roughly half of total US health spending, but benefits, cost-sharing, and networks vary widely between plans, with little overall coordination. In 2023, private health insurance spending accounted for 30 percent of total national health expenditures, Medicare covered 21 percent, and Medicaid covered 18 percent. Most of the remainder was either paid out of pocket by private citizens or was written off by providers as uncollectible.
Here’s where it gets expensive. U.S. health care spending grew 7.5 percent in 2023, reaching $4.9 trillion or $14,570 per person, accounting for 17.6 percent of the nation’s GDP, and national health spending for 2024 is expected to have exceeded $5.3 trillion or 18% of GDP, and health spending is expected to grow to 20.3 percent of GDP by 2033.
For a typical American family, the costs are real and rising. In 2024, the estimated cost of healthcare for a family of four in an employer-sponsored health plan was $32,066.
The European Landscape
Europe doesn’t have one healthcare model—it has several, and they’re all quite different from what we have in the States. Most of the 35 countries in the European Union have single-payer healthcare systems, but the details vary considerably.
Countries like the UK, Sweden, and Norway operate what are essentially single-payer systems where it is solely the government who pays for and provides healthcare services and directly owns most facilities and employs most clinical and related staff with funds from tax contributions. Then you have countries like Germany, and Belgium that use “sickness funds”—these are non-profit funds that don’t market, cherry pick patients, set premiums or rates paid to providers, determine benefits, earn profits or have investors. They’re quasi-public institutions, not private insurance companies like we know them in America. Some systems, such as the Netherlands or Switzerland, rely on mandatory individually purchased private insurance with tight regulation and subsidies, achieving universal coverage with a structured, competitive market.
The French System
France is particularly noted for a successful universal, government-run health insurance system usually described as a single-payer with supplements. All legal residents are automatically covered through the national health insurance program, which is funded by payroll taxes and general taxation.
Most physicians and hospitals are private or nonprofit, not government employees or facilities. Patients generally have free choice of doctors and specialists, though coordinating through a primary care physician improves access and reimbursement. The national insurer pays a large portion of medical costs (often 70–80%), while voluntary private supplemental insurance covers most remaining out-of-pocket expenses such as copays and deductibles.
France is known for spending significantly less per capita than the United States. Cost controls come from nationally negotiated fee schedules and drug pricing rather than limits on access.
What’s striking is that in 2019, US healthcare spending reached $11,072 per person—over double the average of $5,505 across wealthy European nations. Yet despite spending roughly twice as much per person, American health outcomes often lag behind.
The Outcomes Question
This is where the comparison gets uncomfortable for American exceptionalism. The U.S. has the lowest life expectancy at birth among comparable wealthy nations, the highest death rates for avoidable or treatable conditions, and the highest maternal and infant mortality.
In 2023, life expectancy in comparable countries was 82.5 years, which is 4.1 years longer than in the U.S. Japan manages this with healthcare spending at just $5,300 per capita, while Americans spend more than double that amount.
Now, it’s important to note that healthcare systems don’t operate in a vacuum. Life expectancy is influenced by many factors beyond medical care—diet, exercise, smoking, gun violence, drug overdoses, and social determinants of health all play roles. But when you’re spending twice as much and getting worse results, it suggests the system itself might be part of the problem.
Advantages of Single-Payer Systems
The case for single-payer rests on several compelling points. First, administrative simplicity translates to real cost savings. A study found that the administrative burden of health care in the United States was 27 percent of all national health expenditures, with the excess administrative cost of the private insurer system estimated at about $471 billion in 2012 compared to a single-payer system like Canada’s. That’s over $1 out of every $5 of total healthcare spending just going to paperwork, billing disputes, and insurance company profit and overhead before any patient receives care.
Universal coverage is another major advantage. In a properly functioning single-payer system, nobody goes bankrupt from medical bills, nobody delays care because they can’t afford it, and nobody loses coverage when they lose their job. The peace of mind that comes with knowing you’re covered regardless of employment status or pre-existing conditions is difficult to quantify but enormously valuable.
Single-payer systems also have significant negotiating power. When one entity is buying drugs and services for an entire nation, pharmaceutical companies and medical device manufacturers have much less leverage to charge whatever they want. This helps explain why prescription drug prices in other countries are often a fraction of prices in the U.S.
Disadvantages and Trade-offs
The critics of single-payer systems aren’t wrong about everything. Wait times are a genuine concern in some systems. When prices and overall budgets are tightly controlled, some countries experience longer waits for selected elective surgeries, imaging, or specialty visits, especially if investment lags demand.
In 2024, Canadian patients experienced a median wait time of 30 weeks between specialty referral and first treatment, up from 27.2 weeks in 2023, with rural areas facing even longer delays. For procedures like elective orthopedic surgery, patients wait an average of 39 weeks in Canada.
However, it’s crucial to understand that wait times are not a result of the single-payer system itself but of system management, as wait times vary significantly across different single-payer and social insurance systems. Many European countries with universal coverage don’t experience the same wait time issues that plague Canada.
The transition costs are also substantial. Moving from our current system to single-payer would disrupt a massive industry. Over fifteen percent of our economy is related to health care, with half spent by the private sector. Around 160 million Americans currently have insurance through their employers, and transitioning all of them to a government-run plan would be an enormous administrative and political challenge.
A large national payer can be slower to change benefit designs or adopt new payment models; shifting political majorities can affect funding levels and benefit generosity.
Taxes would need to increase significantly to fund such a system, though proponents argue this would be offset by the elimination of insurance premiums, deductibles, and co-pays. It’s essentially a question of whether you’d rather pay through taxes or through premiums—the money has to come from somewhere.
Advantages of America’s Mixed System
Our current system does have some genuine strengths. Innovation thrives in the American healthcare market. The profit motive, for all its flaws, does drive pharmaceutical research and medical device development. American medical schools and research institutions lead the world in many areas of medicine. Academic medical centers and specialty hospitals deliver advanced procedures and complex care that attract patients internationally.
The system also offers more choice for those who can afford it. If you have good insurance, you typically face shorter wait times for elective procedures and can often see specialists without lengthy delays. Americans with high-quality employer-sponsored coverage give their plans relatively high ratings.
Competition between providers can theoretically drive quality improvements, though this effect is often undermined by the complexity of the market and the difficulty consumers face in shopping for healthcare.
Disadvantages of the Current U.S. System
The most glaring problem is simple: The United States remains the only developed country without universal healthcare, and 30 million Americans remain uninsured despite gains under the Affordable Care Act, and many of these gains will soon be lost. Being uninsured in America isn’t just an inconvenience—it can be deadly. People delay care, skip medications, and avoid preventive screenings because of cost concerns.
The administrative complexity is staggering. Doctors spend enormous amounts of time dealing with insurance companies, prior authorizations, and billing disputes. Hospitals employ armies of billing specialists just to navigate the maze of different insurance plans, each with its own rules, formularies, and coverage determinations. U.S. administrative costs account for ~25% of all healthcare spending, among the highest in the world.
Medical bankruptcy is uniquely American. Even people with insurance can find themselves financially devastated by serious illness. High deductibles, surprise bills, and out-of-network charges create a minefield of potential financial catastrophe. Studies of U.S. bankruptcy filings over the past two decades have consistently found that medical bills and medical problems are a major factor in a large share of consumer bankruptcies. Recent summaries suggest that roughly two‑thirds of US personal bankruptcies involve medical expenses or illness-related income loss, and around 17% of adults with health care debt report declaring bankruptcy or losing a home because of that debt.
The system is also profoundly inequitable. Quality of care often depends more on your job, your income, and your zip code than on your medical needs. Out-of-pocket costs per capita have increased as compared to previous decades and the burden falls disproportionately on those least able to afford it.
What Europe Shows Us
The European experience demonstrates that there isn’t one “right” way to achieve universal coverage. The UK’s NHS, Germany’s sickness funds, and France’s hybrid system all manage to cover everyone at roughly half the per-capita cost of American healthcare. Universal Health Coverage exists in all European countries, with healthcare financing almost universally government managed, either directly through taxation or semi-directly through mandated and government-subsidized social health insurance.
They’ve accomplished this through various combinations of centralized negotiation of drug prices, global budgets for hospitals, strong primary care systems that serve as gatekeepers to more expensive specialist care, emphasis on preventive services, and regulation that prevents insurance companies from cherry-picking healthy patients.
Are these systems perfect? No. One of the major disadvantages of centralized healthcare systems is long wait lists to access non-urgent care, though Americans often wait as long or longer for routine primary care appointments as do patients in most universal-coverage countries. Many European countries are wrestling with funding challenges as populations age and expensive new treatments become available. But they’ve solved the fundamental problem that America hasn’t: they ensure everyone has access to healthcare without the risk of financial ruin.
The Path Forward?
The debate over healthcare in America often presents false choices. We don’t have to choose between Canadian-style single-payer and our current system—there are multiple models we could adapt. We could move toward a German-style system with heavily regulated non-profit insurers. We could create a robust public option that competes with private insurance. We could expand Medicare gradually by lowering the eligibility age over time.
What’s clear from international comparisons is that the status quo is unusually expensive and produces mediocre results. We’re paying premium prices for economy outcomes. Whether single-payer is the answer depends partly on your priorities. Do you value universal coverage and cost control more than unlimited choice? Are you willing to accept potentially longer wait times for non-urgent care in exchange for lower costs and universal access? How much do you trust government to manage a program this large?
These aren’t easy questions, and reasonable people disagree. But the evidence from Europe suggests that universal coverage at reasonable cost is achievable—it just requires us to make some choices about what we value most in a healthcare system.
Sources: